Company Profile
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.(CEO & Director)
Sector
Healthcare
Industry
Biotechnology
Employees
2.5K
Beta
0.27
Forward P/E
21.8
52W High
$495.55
52W Low
$283.10
Profit Margin
12.6%
Operating Margin
23.0%
Return on Equity
90.4%
Revenue Growth
96.4%
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATT...
Valuation
Market Cap$39.01B
P/E (TTM)73.39
P/S (TTM)8.36
EV/EBITDA33.64
Cash Flow
FCF Yield+0.5%
SBC Adj. FCF Yield-0.2%
SBC Impact144.1%
Margins & Growth
Profit Margin17.6%
Operating Margin23.0%
Revenue YoY96.4%
Earnings YoY--
Balance
Cash$1.71B
Debt$677.72M
Net Cash$1.03B
Dividend
Dividend Yield--
Payout Ratio--
Quarterly Payout--